⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963435 | 1.00 | — | — | |
| SCHEMBL14395912 | 1.00 | — | — | |
| SCHEMBL19245279 | 1.00 | — | — | |
| SCHEMBL6620459 | 1.00 | — | — | |
| SCHEMBL15172640 | 1.00 | — | — | |
| SCHEMBL16741732 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL30030537 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL30031362 | 0.96 | — | — | |
| Bicarbonate SCHEMBL8038806 | 0.85 | SLC1A3 (0.42) | — | |
| SCHEMBL13729498 | 0.79 | CA1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161281-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220435-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023212231-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212239-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2022217276-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20200216417-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2020-07-09 | — | — | US | disclosed |
| EP-2602255-B1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8648072-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120264754-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2012-10-18 | — | — | US | disclosed |
| US-8217038-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110257178-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011044370-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-6677337-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2003-12-04 | — | — | US | disclosed |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. | 2002-07-04 | — | — | US | disclosed |